Search results
Showing 691 to 705 of 726 results for innovative
People in England could benefit from new endometrial cancer treatment
Innovative new drug for treating endometrial cancer in adults recommended by NICE as an option for use within the Cancer Drugs Fund.
NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the new class of Alzheimer’s drugs but key issues need to be considered, a new report has found.
NICE has approved mavacamten, the first treatment that specifically targets a heart condition called obstructive hypertrophic cardiomyopathy (HCM). It means around 7,000 people will now be able to access the treatment on the NHS.
Around 105,000 people with type 1 diabetes could benefit from NICE’s draft recommendation
Around 1,500 people aged 12 years and over with melanoma are set to benefit from pembrolizumab, a drug that reduces the chance of it returning.
Change in treatment for people with early breast cancer to benefit around 4,000
Around 4,000 people are set to benefit from a change in treatment for early breast cancer following provisional approval by NICE of abemaciclib in combination with hormone therapy.
New guidance recommends transplant with good bacteria taken from poo
Up to 500 people each year could be treated using faecal microbiota transplant for multiple recurrences of Clostridium difficile infections.
NICE launches refreshed support service for life sciences industry
NICE has launched its refreshed support service for the life sciences sector, NICE Advice.
NICE launches first modular update to its methods and processes
NICE’s methods and processes now include a proportionate approach to technology appraisals, and a new way of updating recommendations on COVID-19 treatments.
Innovative technology to detect abnormal heart rhythms recommended by NICE
Zio XT is the first assessment, via the NICE digital health technologies guidance development pilot project, to be recommended for NHS use.
A safe space for bold ideas – implementing a sandbox approach in health technology assessment
Colleagues in our Science Policy and Research Programme discuss their international research, paving the way for next generation health technology assessment.
NICE leads the way to develop a new approach to routinely value and pay for crucial antimicrobials
James Love-Koh talks about the next steps for the 3-year project to develop a routine framework for evaluating and paying for new antimicrobials.
Around 400 people with advanced breast cancer are set to benefit from a new treatment
Tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading.
NICE is getting ready for the end of the transition period after Brexit
NICE has a key role in ensuring the UK remains a destination of choice for the life sciences sector.
Changes to the way medicines and other health technologies are evaluated by NICE have now been incorporated into NICE’s new combined methods and processes manual and topic selection manual published today (31 January 2022).